The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions.
Implementing guardrails for artificial intelligence (AI) in biopharma is crucial for ensuring effective, safe, and compliant use of this powerful technology.
Limited Partners (LPs) are at the heart of the biotech funding ecosystem—these crucial players ignite the funding flywheel that drives biotech innovation.
Let’s explore the four most common use cases for an AI-powered drug pipeline analysis platform and how they support strategic decision-making in biopharma.
Artificial Intelligence covers a range of algorithmic applications and outputs. Sometimes, AI hallucinates, so how does Vibe Bio deliver trustworthy outputs?
In biopharma, pipeline analysis provides comprehensive insights into the lifecycle of drug candidates, from discovery through clinical trials to market launch.
Vibe Bio is doing extraordinary work to change drug development: from funding next-generation therapies to helping others identify the highest potential cures.